LILRB2 and non-small cell lung carcinoma: For example, in NSCLC, ILT4 overexpression suppresses the tumor immunity by impairing T cell response and recruiting M2-like TAMs, preventing immunosuppression and enhancing the efficacy of PD-L1 inhibitor in EGFR wild-type NSCLC [9].